| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.22 | 2e-09 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.19 | 8e-09 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | 0.18 | 7e-07 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.18 | 8e-07 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | Gemcitabine | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |